Other Earnings and Cash Flow Stats:
ARGENX SE ( ARGX ) Net Income TTM ($MM) is -64.26
ARGENX SE ( ARGX ) Operating Income TTM ($MM) is -329.49
ARGENX SE ( ARGX ) Owners' Earnings Annual ($MM) is 0.00
ARGENX SE ( ARGX ) Current Price to Owners' Earnings ratio is 0.00
ARGENX SE ( ARGX ) EBITDA TTM ($MM) is -198.26
ARGENX SE ( ARGX ) EBITDA Margin is -1.66%
Capital Allocation:
ARGENX SE ( ARGX ) has paid 0.00 dividends per share and bought back -7.634357 million shares in the past 12 months
ARGENX SE ( ARGX ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
ARGENX SE ( ARGX ) Interest-bearing Debt ($MM) as of last quarter is 0
ARGENX SE ( ARGX ) Annual Working Capital Investments ($MM) are 151
ARGENX SE ( ARGX ) Book Value ($MM) as of last quarter is 4262
ARGENX SE ( ARGX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
ARGENX SE ( ARGX ) has 1438 million in cash on hand as of last quarter
ARGENX SE ( ARGX ) has 499 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ARGENX SE ( ARGX ) has 65 common shares outstanding as of last quarter
ARGENX SE ( ARGX ) has 0 million USD of preferred stock value
Academic Scores:
ARGENX SE ( ARGX ) Altman Z-Score is 46.65 as of last quarter
ARGENX SE ( ARGX ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
ARGENX SE ( ARGX ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of ARGENX SE ( ARGX ) for the amount of $ on
0.00% of ARGENX SE ( ARGX ) is held by insiders, and 59.57% is held by institutions
ARGENX SE ( ARGX ) went public on 2017-05-18
Other ARGENX SE ( ARGX ) financial metrics:
FCF:-422.43
Unlevered Free Cash Flow:0.00
EPS:5.56
Operating Margin:2.47
Gross Profit Margin:89.69
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-3.05
Beta:0.77
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ARGENX SE ( ARGX ) :
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
DISCLAIMER
This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.